Back to Search
Start Over
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
- Source :
-
Journal of gynecologic oncology [J Gynecol Oncol] 2017 Jan; Vol. 28 (1), pp. e15. - Publication Year :
- 2017
-
Abstract
- Objective: To evaluate the efficacy and toxicity of paclitaxel plus carboplatin (TC)-based concurrent chemoradiotherapy (CCRT) followed by consolidation chemotherapy in the International Federation of Gynecology and Obstetrics (FIGO) stage IIIB/IVA cervical cancer patients.<br />Methods: We reviewed the medical records of FIGO stage IIIB/IVA cervical cancer patients (n=30) who had been intended to be treated with TC-based CCRT followed by consolidation chemotherapy (TC-CCRT-group) from April 2012-May 2016. Patients who had been treated with CCRT involving a single platinum agent (CCRT-group; n=52) or definitive radiotherapy alone (RT-group; n=74) from January 1997-September 2012 were also identified and used as historical controls. Survival was calculated using the Kaplan-Meier method and compared using the log-rank test.<br />Results: Of the 30 patients included in the TC-CCRT-group, 22 patients (73.3%) completed the planned TC-based CCRT. The most frequently observed acute grade 3/4 hematological toxicities were leukopenia and neutropenia, and diarrhea was the most common acute grade 3/4 non-hematological toxicity. After a median follow-up of 35 months, 9 patients (30.0%) had developed recurrent disease. The patients' estimated 3-year progression-free survival (PFS) and overall survival (OS) rates were 67.9% and 90.8%, respectively. In comparisons with historical control groups, the survival outcomes of TC-CCRT-group was significantly superior to CCRT-group in terms of OS (p=0.011) and significantly superior to RT-group in terms of both PFS (p=0.009) and OS (p<0.001).<br />Conclusion: TC-based CCRT followed by consolidation chemotherapy is safe and effective. A randomized controlled study needs to be conducted to further evaluate the efficacy of this multimodal approach in this patient population.<br />Competing Interests: No potential conflict of interest relevant to this article was reported.
- Subjects :
- Adult
Aged
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Carboplatin administration & dosage
Carboplatin adverse effects
Carcinoma, Squamous Cell mortality
Carcinoma, Squamous Cell pathology
Case-Control Studies
Cisplatin adverse effects
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Middle Aged
Neoplasm Staging
Paclitaxel administration & dosage
Paclitaxel adverse effects
Retrospective Studies
Survival Rate
Uterine Cervical Neoplasms mortality
Uterine Cervical Neoplasms pathology
Young Adult
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Squamous Cell therapy
Chemoradiotherapy methods
Consolidation Chemotherapy methods
Uterine Cervical Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2005-0399
- Volume :
- 28
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of gynecologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 27958682
- Full Text :
- https://doi.org/10.3802/jgo.2017.28.e15